Analyst: Improved market conditions will support Lundbeck's key products in Q1
On Wednesday, when the pharmaceutical firm hands in its first quarterly report for 2022, onlookers should pay attention to four key products, says a Sydbank analyst.
by marketwire, translated by daniel pedersen
As the pandemic has eased up, and restrictions have been lifted, pharmaceutical firm Lundbeck’s market conditions have improved. This should be evident in the firm’s first quarterly report, which is slated to release on Wednesday, an analyst says.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Lundbeck poaches Zealand Pharma VP
For subscribers
